Compliance with galantamine and vitamin E in Alzheimer's disease patients: The care trial.

被引：0
|
作者：
Feely, M
Amatniek, J
机构：
[1] Acad Unit Mol Vasc Med, Leeds, W Yorkshire, England
[2] Janssen Pharmaceut Prod, LP, Titusville, NJ USA
来源：
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY | 2003年 / 51卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R592 [老年病学]; C [社会科学总论];
学科分类号：
03 ; 0303 ; 100203 ;
摘要：
P184
引用
收藏
页码：S105 / S106
页数：2
相关论文
共 50 条
  • [21] Effect of galantamine on attention in patients with Alzheimer's disease combined with cerebrovascular disease
    Park, Jeong Jin
    Choi, Seong Hye
    Kim, SangYun
    Lee, Ae Young
    Moon, So Young
    Lee, Jun Hong
    Kwon, Jae Cheol
    Park, Kyung Won
    Ku, Bon D.
    Han, Hyun Jeong
    Kim, Eun-Joo
    Shim, Yong S.
    GERIATRICS & GERONTOLOGY INTERNATIONAL, 2017, 17 (10) : 1661 - 1666
  • [22] Therapeutic continuity in Alzheimer's disease: Switching patients to galantamine - Overview
    Morris, JC
    CLINICAL THERAPEUTICS, 2001, 23 : A1 - A2
  • [23] Vitamin E and memantine in Alzheimer's disease: Clinical trial methods and baseline data
    Dysken, Maurice W.
    Guarino, Peter D.
    Vertrees, Julia E.
    Asthana, Sanjay
    Sano, Mary
    Llorente, Maria
    Pallaki, Muralidhar
    Love, Susan
    Schellenberg, Gerard D.
    McCarten, J. Riley
    Malphurs, Julie
    Prieto, Susana
    Cheng, Peijun
    Loreck, David J.
    Carneyk, Sara
    Trapp, George
    Bakshi, Rajbir S.
    Mintzer, Jacobo E.
    Heidebrink, Judith L.
    Vidal-Cardona, Ana
    Arroyo, Lillian M.
    Cruz, Angel R.
    Kowall, Neil W.
    Chopra, Mohit P.
    Craft, Suzanne
    Thielke, Stephen
    Turvey, Carolyn L.
    Woodman, Catherine
    Monnell, Kimberly A.
    Gordon, Kimberly
    Tomaska, Julie
    Vatassery, Govind
    ALZHEIMERS & DEMENTIA, 2014, 10 (01) : 36 - 44
  • [24] Benefits of galantamine treatment in patients with 'very mild' Alzheimer's disease
    Orgogozo, JM
    van Baelen, B
    Schwalen, S
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2004, 14 : S329 - S329
  • [25] Galantamine improves attention in patients with mild to moderate Alzheimer's disease
    Schwalen, S
    Vellas, B
    van Baelen, B
    Hammond, G
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2004, 14 : S328 - S329
  • [26] Galantamine (Reminy®) benerits patients with mild Alzheimer's disease and their caregivers
    Lang, CJG
    Hager, K
    Rösler, M
    Schwalen, S
    AKTUELLE NEUROLOGIE, 2002, 29 (08) : 402 - 408
  • [27] Galantamine population pharmacokinetics in patients with Alzheimer's disease: Modeling and simulations
    Piotrovsky, V
    Van Peer, A
    Van Osselaer, N
    Armstrong, M
    Aerssens, J
    JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 43 (05): : 514 - 523
  • [28] A naturalistic study of galantamine for Alzheimer's disease
    Brodaty, Henry
    Woodward, Michael
    Boundy, Karyn
    Barnes, Nicola
    Allen, Gabrielle
    CNS DRUGS, 2006, 20 (11) : 935 - 943
  • [29] A Naturalistic Study of Galantamine for Alzheimer’s Disease
    Henry Brodaty
    Michael Woodward
    Karyn Boundy
    Nicola Barnes
    Gabrielle Allen
    CNS Drugs, 2006, 20 : 935 - 943
  • [30] Galantamine hydrobromide: An agent for Alzheimer's disease
    Zarotsky, V
    Sramek, JJ
    Cutler, NR
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2003, 60 (05) : 446 - 452
12345